Pipeline Watch: Phase III Starts With Gilteritinib, Lumateperone, Pro 140
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Daiichi's Quizartinib Looks To Join Novartis' Rydapt In AML
Phase III results for Daiichi Sankyo's FLT3 targeting quizartinib are in, but it's unclear as yet how the data will affect a niche, targeted hematology/oncology market.
Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
Alexion Restructuring Deemed A Necessary Evil
The painful cuts in the workforce and HQ relocation planned by the new executive team at Alexion may be necessary for the long-term health of the company.